Female pattern hair loss (FPHL) — also called androgenetic alopecia in women — affects an estimated 8% of women under 30 and up to 40% of women over 70, according to the British Association of Dermatologists. It is the most common cause of hair thinning in women, yet it remains under-discussed in pharmacy consultations.
The UK government's renewed commitment to improving healthcare for women, outlined on 15 April 2026, highlights persistent gaps in how women's health concerns are heard and addressed. Hair loss, while not life-threatening, has a significant impact on quality of life and self-esteem — and pharmacy is often the first point of contact.
What female pattern hair loss looks like
Unlike male pattern baldness, FPHL rarely causes complete baldness. Instead, women typically notice:
- Gradual thinning at the crown and along the central parting (the "Christmas tree" pattern)
- Increased hair shedding, particularly noticeable on pillows and in the shower
- A widening parting line over months or years
- Preservation of the frontal hairline, which usually remains intact
The Ludwig classification grades FPHL from I (mild thinning) to III (extensive thinning visible through the hair). Most women presenting at pharmacy counters will be Ludwig grade I or II.
Causes and contributing factors
FPHL has a strong genetic component. Hormonal changes — particularly declining oestrogen levels around menopause — accelerate the process. Other contributing factors include:
| Factor | Notes |
|---|---|
| Iron deficiency | Common in women with heavy periods; ferritin below 40 µg/L may worsen shedding |
| Thyroid dysfunction | Both hypo- and hyperthyroidism cause diffuse hair loss |
| Polycystic ovary syndrome (PCOS) | Androgen excess causes both hair thinning on the scalp and excess body hair |
| Stress (telogen effluvium) | Acute stress triggers temporary diffuse shedding 2–3 months later; distinct from FPHL but often confused |
| Medications | Some contraceptives, retinoids, anticoagulants and antidepressants list hair thinning as a side effect |
Pharmacy teams should be alert to these differential diagnoses. A woman presenting with sudden-onset diffuse shedding, patchy loss, or scalp inflammation should be referred to a GP or dermatologist rather than offered OTC treatment.
The pharmacy treatment: minoxidil
Minoxidil is the only medicine licensed in the UK for the treatment of female pattern hair loss without prescription. It is available as:
- Regaine for Women (2% topical solution) — the original branded product, applied twice daily
- Regaine for Women Once a Day (2% foam) — once-daily application
- Generic minoxidil 2% — available from several manufacturers at lower cost
The 5% strength minoxidil products widely sold for male pattern baldness are not licensed for women in the UK, though some dermatologists prescribe them off-label. Pharmacy teams should not recommend 5% products to women without a prescription.
What to tell patients
- Results take 3–6 months of consistent use before visible improvement
- Initial shedding (weeks 2–8) is common and expected — it indicates the treatment is working by pushing telogen hairs into a new growth phase
- If treatment is stopped, any regained hair will gradually thin again over 3–6 months
- Minoxidil must be applied to a dry scalp and left for at least 4 hours before washing
- Patients should avoid applying minoxidil immediately before bed to prevent transfer to pillows and accidental facial hair growth
Contraindications and cautions
- Not recommended in pregnancy or breastfeeding
- Should not be used on inflamed, infected or broken scalp skin
- Patients with cardiovascular conditions should consult their GP first (minoxidil was originally developed as an antihypertensive)
- Scalp irritation and contact dermatitis occur in a minority of users
Supplements: what the evidence supports
Several supplements are marketed for hair health. The evidence base is limited:
| Supplement | Evidence |
|---|---|
| Biotin (vitamin B7) | Deficiency causes hair loss, but deficiency is rare in the UK. No benefit shown in supplementation when levels are normal |
| Iron | Supplementation helps if ferritin is low (<40 µg/L). Does not help if iron status is normal |
| Zinc | Deficiency is associated with hair loss; supplementation has weak evidence in non-deficient individuals |
| Marine collagen | Limited clinical trial data; no NICE or BAD recommendation |
| Viviscal / Nourkrin | Proprietary blends with some industry-funded RCT data; not independently replicated |
The most evidence-based pharmacy advice is: check iron and thyroid levels with the GP before spending on supplements.
When to refer
Pharmacy teams should refer women to their GP when:
- Hair loss is sudden, patchy, or associated with scalp scarring
- There are signs suggesting an underlying condition (fatigue, weight change, menstrual irregularity, excess body hair)
- The patient is under 18
- Hair loss began after starting a new medication
- OTC minoxidil has been used for 12 months without improvement
- The patient requests prescription-only options (spironolactone, finasteride off-label)
Pharmacy's role in the conversation
Hair loss is a sensitive subject. Many women delay seeking help because they feel it is trivial or because they have been dismissed in previous healthcare consultations. The renewed Women's Health Strategy explicitly calls for women's concerns to be taken seriously — and pharmacy is well placed to deliver on that commitment.
A good pharmacy consultation involves asking about duration, pattern, family history, diet, stress, medications, and menstrual history before recommending a product. PharmSee tracks over 1,742 active pharmacy vacancies across England, reflecting a workforce under pressure — but counter conversations like these are where pharmacy demonstrates its unique clinical value.
Caveats
Prevalence estimates are drawn from British Association of Dermatologists guidelines. Supplement evidence summaries reflect published systematic reviews and NICE guidance as of April 2026. PharmSee does not track OTC product sales data. The vacancy figure of 1,742 reflects PharmSee's monitoring of 11 public job sources and may not capture all roles (see data sources).
Sources: British Association of Dermatologists, NICE Clinical Knowledge Summaries, MHRA product licensing data, PharmSee vacancy database (April 2026), BBC News (15 April 2026).